Endometrial cancer is the fourth most common malignancy among American women. The National Cancer Institute estimates that close to 50,000 women will be diagnosed with endometrial cancer in 2013; for a majority of women with aggressive, high-grade tumors, the 5-year survival rate is approximately 16%.

Using data-sifting algorithms developed by computer scientists at Brown University, researchers are beginning to untangle the complex genetics of cancer. In a new study published in the New England Journal of Medicine, investigators have outlined the most complete genetic profile of acute myeloid leukemia (AML). This research is expected to lead to new treatments for AML based on the unique genetics of each patient.

The American Society of Hematology (ASH) announced the first recipients of its new program, ASH Bridge Grants, that is designed to provide hematologists with research funding to mitigate the reduction in research support from the National Institutes of Health (NIH) as a result of the recent cuts to federal funding, including a $1.6-billion cut in 2013 and additional cuts that will take place during the next several years as a result of sequestration.

Hollywood, FL—Stakeholders from across the field of oncology gathered at the Third Annual Conference of the Association for Value-Based Cancer Care (AVBCC) to network and to explore ways to adapt to a rapidly changing landscape.

Hollywood, FL—At the Third Annual Conference of the Association for Value-Based Cancer Care, James Lang, PharmD, Vice President of Pharmacy Services at BlueCross BlueShield of Michigan (BCBSM), shared his company’s approach to new managed market challenges.

Hollywood, FL—“The overarching issue that brings us to the AVBCC Annual Conference is that rising healthcare costs are unsustainable,” said Jennifer Malin, MD, PhD, Medical Director of Oncology at WellPoint, Inc, who spoke at the Third Annual Conference of the Association for Value-Based Cancer Care from the perspective of managed markets.

The US Food and Drug Admini­s­tration (FDA) approved the technetium Tc 99m tilmanocept ([Tc 99m], Lymphoseek Injection; Navidea Biopharmaceuticals)—a novel radioactive receptor-targeted tracer for intraoperative lymphatic mapping—for use in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining nodes. Tc 99m is an imaging drug that helps locate lymph nodes; it is not a cancer imaging drug.

The US Food and Drug Admini­s­tration (FDA) approved the technetium Tc 99m tilmanocept ([Tc 99m], Lymphoseek Injection; Navidea Biopharmaceuticals)—a novel radioactive receptor-targeted tracer for intraoperative lymphatic mapping—for use in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining nodes. Tc 99m is an imaging drug that helps locate lymph nodes; it is not a cancer imaging drug.

In February 2013, the FDA granted Breakthrough Designation for ibrutinib (Johnson & Johnson) as monotherapy for the treatment of patients with 1 of 2 conditions—refractory or relapsed mantle-cell lymphoma or Waldenström’s macroglobulinemia— both of which are B-cell malignancies. In April 2013, the FDA granted ibrutinib a third Breakthrough Designation for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with chromosome 17p deletion. (April 8, 2013)

The FDA has granted a Break­through Therapy designation for the investigational drug palbociclib (PD-0332991; Pfizer)—an oral, selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6—for the potential treatment of patients with breast cancer. CDKs 4 and 6 are related kinases that enable tumor-cell progression, which enhances cell division and DNA replication. Inhibition of CDKs 4 and 6 with palbociclib has been shown to inhibit tumor-cell growth and DNA replication.

Page 4 of 5
Results 31 - 40 of 44
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology